All News

Recommendations abound for when women at average risk for breast cancer should begin yearly mammography screening, ranging from age 40 to 50. Questions remain, however, on the optimal age at which to stop. However, with over 50% of women older than age 75 still undergoing mammography, is there a truly safe age at which to stop what has been shown to be a life-saving practice if it does not decrease their mortality from breast cancer?

The association between migraine and several gastrointestinal (GI) disorders prompted investigations into the bidirectional relationship between the GI system and central nervous system. Researchers call this association the “gut-brain axis,” and they evaluated direct and indirect evidence linking migraines to the axis in a recent review published in The Journal of Headache and Pain.

The FDA approved Eli Lilly’s dulaglutide (Trulicity) for the reduction of major adverse cardiovascular events in adults with type 2 diabetes (T2D), with and without established cardiovascular disease (CVD), according to a press release.

Researchers developed a structurally colored contact lens sensor with tunable colors to assist in point-of-care diagnoses of common eye diseases, according to a study published in the Journal of Materials Chemistry B.

Nonprofit hospitals with the highest net income were shown in a study to devote the smallest proportion of earnings to charity care; FDA approves a novel drug to lower low-density lipoprotein cholesterol (LDL-C); the White House is seeking emergency funding from Congress to fight the novel coronavirus.

Drug developers have made significant strides in understanding narcolepsy in recent years. Now, those advances are translating into a robust pipeline of potential new therapies.

In a major study of a Chinese medical insurance database, investigators found the prevalence and incidence of the disease in China is similar to those of its neighbors, but lower than countries in the West.

With our current issue of Evidence-Based Oncology™ focusing on clinical pathways in cancer care, we look back at one of our most-read papers of 2016.

The research revealed 5 risk factors for stroke for patients with migraine with aura.

When time to first treatment ranged from 31 to 90 days for patients with breast cancer, doctors had more time for extensive diagnostic workups without compromising survival rates.

The most popular stories of the week on AJMC®.

Though rare, patients with both autoimmune hemolytic anemia (AHIA) and non-Hodgkin lymphoma face stark odds of long-term survival. A new study lends insights into how to best diagnose and treat those patients.

By age 3, children involved in the survey developed wheeze, atopy, or asthma—possibly linked to their parents’ use of common household cleaning products.

This week, top managed care stories included an additional setback for Medicaid work rules; another study finding more benefits from SGLT2 inhibitors; researchers finding unwanted end-of-life care causes stress.

Millennials have increaseing incidence of liver disease related to alcohol consumption; the EPA will regulate 2 chemicals in drinking water; unpaid caregivers are on the rise in the United States.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

As a whole, the public does not realize that certain health coverage benefits stem from the Affordable Care Act (ACA).

Circulation, a peer-reviewed journal of the American Heart Association, just released its fourth annual Go Red for Women issue, in which researchers from the Smidt Heart Institute at Cedars-Sinai note the stark disparities in how heart disease manifests in women and men. For women, sudden cardiac death is often the first sign they even have heart disease.

In 2019, the US Department of Defense (DoD) and Department of Veterans Affairs (VA) approved clinical practice guidelines regarding management and treatment of chronic insomnia disorder and obstructive sleep apnea in VA and DoD patients. The VA/DoD Evidence-Based Practice Work Group formulated the framework to enable more effective screening, treatment, and managements of these diseases, according to a review published in Annals of Internal Medicine.

A study found potential age bias in heart care for patients on different sides of their 80th birthday; 2 passengers from the Diamond Princess cruise ship die of coronavirus; California Governor Gavin Newsom outlined several mental health proposals to address homelessness in the state.

It can be difficult to notice when a patient is transitioning from relapsing-remitting multiple sclerosis to the secondary progressive form. Soon, neurologists may be able to use a digital tool to catch it.

There’s significant evidence that some patients with far-advanced glaucoma are able to perform more tasks than others. Yet, it’s difficult to distinguish these patients from each other. A new study proposes a way to find out.

Cardinal Innovations Healthcare is the largest specialty health plan in the country, insuring more than 850,000 North Carolinians with complex needs. Using a community-based model of care management, Cardinal Innovations has led the way in developing services, processes and solutions that improve the lives of our members and their families. Recognized for operational excellence, innovative solutions and superior outcomes for members, accuracy and speed of payments to providers, and cost-effective funds management, Cardinal Innovations is a leading healthcare company in the United States.

Several clinical trials have found mesenchymal stem cell therapy effective in treating neural damage in patients with multiple sclerosis (MS), according to a review published in Stem Cell Investigation.

Higher out-of-pocket (OOP) drug costs for 3 common neurologic conditions—Parkinson disease, Alzheimer disease, and peripheral neuropathy—were associated with lower medication adherence among patients, which can potentially intensify symptom burden and result in higher costs.

Radium-223’s (Ra-223) low levels of alpha particle radiation induce double-strand DNA breaks, which leads to cell apoptosis. Sipuleucel-T (SipT), which is an immunotherapy manufactured from a patient’s peripheral blood mononuclear cells, activates T cells to spur an immune response. Both are used to treat bone-metastatic castration-resistant prostate cancer (CRPC). Study data suggest a synergistic immune effect when Ra-223 is added to treatment with SipT.

The results are in line with earlier studies, and the current review found a link with bladder cancer and lung cancer.